BELLICUM PHARMACEUTICALS INC's ticker is and the CUSIP is 079481404. A total of 25 filers reported holding BELLICUM PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $7,579 | -41.7% | 10,527 | 0.0% | 0.00% | – |
| Q3 2022 | $13,000 | +8.3% | 10,527 | +0.2% | 0.00% | – |
| Q2 2022 | $12,000 | -50.0% | 10,502 | -7.0% | 0.00% | – |
| Q1 2022 | $24,000 | -71.1% | 11,292 | -60.4% | 0.00% | – |
| Q3 2021 | $83,000 | -14.4% | 28,548 | -3.1% | 0.00% | – |
| Q2 2021 | $97,000 | +54.0% | 29,458 | +76.4% | 0.00% | – |
| Q1 2021 | $63,000 | – | 16,698 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SABBY MANAGEMENT, LLC | 159,500 | $563,000 | 0.11% |
| Ikarian Capital, LLC | 500,000 | $1,765,000 | 0.08% |
| Anson Funds Management LP | 99,103 | $350,000 | 0.07% |
| GSA CAPITAL PARTNERS LLP | 66,558 | $235,000 | 0.04% |
| AJU IB Investment Co., Ltd. | 25,651 | $91,000 | 0.03% |
| BOOTHBAY FUND MANAGEMENT, LLC | 53,041 | $187,000 | 0.01% |
| SHUFRO ROSE & CO LLC | 12,941 | $46,000 | 0.00% |
| Baker Brothers Advisors | 249,123 | $879,000 | 0.00% |
| Tekla Capital Management LLC | 6,000 | $21,000 | 0.00% |
| Orion Capital Management LLC | 500 | $2,000 | 0.00% |